Cell line · CVCL_1110
Papers57
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 57
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The ALS- and FTD-associated proteins annexin A11 and CHMP2B act sequentially in plasma membrane repair. | Dev Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MND1 reduces breast cancer chemosensitivity by promoting RAD51-mediated homologous recombination repair. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HSPA6 Promotes Ferroptosis in Triple-Negative Breast Cancer by Rewiring Lipid Metabolism to Potentiate Membrane Lipid Peroxidation. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. | Redox Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cell and Nuclear Size Is Associated with Chromosomal Instability and Tumorigenicity in Cancer Cells That Undergo Whole Genome Doubling. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CENP-E Inhibition Induces Chromosomal Instability and Synergizes with Diverse Microtubule-Targeting Agents in Breast Cancer. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells. | FEBS J | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| FOXM1 is critical for the fitness recovery of chromosomally unstable cells. | Cell Death Dis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Misaligned Chromosomes are a Major Source of Chromosomal Instability in Breast Cancer. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| LAP1 supports nuclear adaptability during constrained melanoma cell migration and invasion. | Nat Cell Biol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1110/papers